TG Therapeutics, Inc. (TGTX) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell diseases. Its primary marketed product is BRIUMVI (ublituximab-xiiy), approved for the treatment of relapsing forms of multiple sclerosis (RMS). The company operates as a single reportable segment and is currently transitioning from a development-focused entity to a commercial organization, having recently achieved profitability.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $161.7 million | $83.9 million | $423.7 million | $220.8 million |
| Net Income | $390.9 million | $3.9 million | $424.1 million | $0.1 million |
| Operating Income | $29.4 million | $12.4 million | $72.8 million | $12.0 million |
| Diluted EPS | $2.43 | $0.02 | $2.62 | $0.00 |
| Cash & Investments | $178.3 million (as of Sept 30, 2025) | |||
| Debt (Loan Payable) | $245.3 million (net of issuance costs) | |||
| Accumulated Deficit | $1.1 billion (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 92% year-over-year for the quarter and 92% year-over-year for the nine-month period. This was driven primarily by a 91% increase in net product revenue from BRIUMVI ($159.3M in Q3 2025 vs. $83.3M in Q3 2024), attributed to greater market penetration in the U.S. and sales to the ex-U.S. partner, Neuraxpharm.
- Profitability Surge: Net income jumped significantly due to a $365.0 million income tax benefit in Q3 2025, resulting from the release of a deferred tax asset valuation allowance. This contrasts with a $0.4 million tax expense in the prior year quarter. Operating income also improved, driven by revenue growth outpacing expense increases.
- Expense Increases: Total costs and expenses rose to $132.3 million in Q3 2025 from $71.4 million in Q3 2024.
- R&D: Increased to $40.9 million (from $20.1M) due to manufacturing costs for subcutaneous ublituximab and clinical trial expenses.
- SG&A: Increased to $63.4 million (from $42.0M) due to expanded commercialization efforts and marketing personnel.
- Cost of Revenue: Increased to $28.1 million (from $9.3M) primarily due to royalties and manufacturing costs.
- Share Repurchases: The company completed its prior $100 million share repurchase program in September 2025, purchasing 2.78 million shares in Q3 alone. A new $100 million repurchase program was authorized in September 2025.
Guidance, Outlook, and Risks
- Liquidity: Management anticipates that current cash, cash equivalents, and investment securities ($178.3 million), combined with projected future revenues, will be sufficient to meet liquidity needs for more than 12 months.
- Product Pipeline:
- BRIUMVI: Commercialization continues in the U.S. and ex-U.S. (via Neuraxpharm). A Phase 3 trial for a subcutaneous formulation has commenced enrollment.
- Azer-cel: An allogeneic CAR T therapy for autoimmune diseases; Phase 1 enrollment for progressive MS has begun.
- Key Risks:
- Commercialization: Dependence on market acceptance of BRIUMVI and reimbursement policies.
- Supply Chain: Reliance on third-party manufacturers (sole source for bulk drug substance). A potential manufacturing deviation affecting one batch of bulk drug substance was identified in Q3 2025, with an estimated potential exposure of $6.0 million, though no loss was deemed probable at the reporting date.
- Regulatory & Legal: Risks related to FDA approvals, post-marketing requirements, and potential tariffs on imported pharmaceuticals (a 100% tariff on branded drugs was announced for Oct 1, 2025, though currently delayed pending negotiations).
- Debt Covenants: The company has a $250 million term loan with Blue Owl Capital maturing in 2029, subject to covenants and interest rate fluctuations.
Investor Verification Checklist
- Verify the sustainability of the income tax benefit ($365M in Q3) and whether it represents a one-time adjustment to the valuation allowance rather than recurring operational cash flow.
- Monitor the resolution of the manufacturing deviation regarding the bulk drug substance batch and any potential impact on supply or inventory reserves.
- Assess the impact of potential tariffs on imported pharmaceuticals on the cost of goods sold, given the reliance on non-U.S. suppliers for active pharmaceutical ingredients.
- Review the progress of the subcutaneous ublituximab Phase 3 trial, as this is critical for expanding the addressable market and competitive positioning.
- Track accounts receivable growth ($265.4M at Sept 30, 2025 vs. $129.2M at Dec 31, 2024) to ensure collection timelines align with cash flow projections.